Page 33 - Read Online

Llamoza-Torres et al. Metab Target Organ Damage 2024;4:40 https://dx.doi.org/10.20517/mtod.2024.64 Page 13 of 18

Ramos-Molina B was not involved in any steps of editorial processing, notably including reviewers’
selection, manuscript handling and decision making. Llamoza-Torres CJ has received speaker and
conference fees, travel expenses from EISAI, MSD and Roche. Fuentes-Pardo M declared that
there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2024.

REFERENCES
1. Hagström H, Shang Y, Hegmar H, Nasr P. Natural history and progression of metabolic dysfunction-associated steatotic liver disease.
Lancet Gastroenterol Hepatol 2024;9:944-56. DOI PubMed
2. Younossi ZM, Stepanova M, Ong J, et al. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver
transplantation in the United States. Clin Gastroenterol Hepatol 2021;19:580-9.e5. DOI PubMed
3. Younossi ZM, Harring M, Younossi Y, Ong JP, Alqahtani SA, Stepanova M. The impact of NASH to liver transplantations with
hepatocellular carcinoma in the United States. Clin Gastroenterol Hepatol 2022;20:2915-7.e1. DOI PubMed
4. Sanyal AJ, Van Natta ML, Clark J, et al; NASH Clinical Research Network (CRN). Prospective study of outcomes in adults with
nonalcoholic fatty liver disease. N Engl J Med 2021;385:1559-69. DOI PubMed PMC
5. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-
analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84. DOI PubMed
6. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease
(NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023;77:1335-47. DOI PubMed PMC
7. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.
Lancet Gastroenterol Hepatol 2022;7:851-61. DOI PubMed
8. Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 2022;19:151-72.
DOI PubMed
9. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic
associated fatty liver disease. Gastroenterology 2020;158:1999-2014.e1. DOI PubMed
10. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new
fatty liver disease nomenclature. J Hepatol 2023;79:1542-56. DOI PubMed
11. Hsu CL, Loomba R. From NAFLD to MASLD: implications of the new nomenclature for preclinical and clinical research. Nat Metab
2024;6:600-2. DOI PubMed PMC
12. Hagström H, Adams LA, Allen AM, et al. The future of international classification of diseases coding in steatotic liver disease: an
expert panel Delphi consensus statement. Hepatol Commun 2024;8:e0386. DOI PubMed PMC
13. Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction-associated steatotic liver disease: update and
impact of new nomenclature on the American association for the study of liver diseases practice guidance on nonalcoholic fatty liver
disease. Hepatology 2024;79:1212-9. DOI PubMed
14. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of
nonalcoholic fatty liver disease. Hepatology 2023;77:1797-835. DOI PubMed PMC
15. Allen AM, Younossi ZM, Diehl AM, Charlton MR, Lazarus JV. Envisioning how to advance the MASH field. Nat Rev Gastroenterol
Hepatol 2024;21:726-38. DOI PubMed
16. Loomba R, Wong VW. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-
associated steatotic liver disease. Aliment Pharmacol Ther 2024;59:150-6. DOI PubMed PMC
17. Canivet CM, Boursier J, Loomba R. New nomenclature for nonalcoholic fatty liver disease: understanding metabolic dysfunction-
associated steatotic liver disease, metabolic dysfunction- and alcohol-associated liver disease, and their implications in clinical
practice. Semin Liver Dis 2024;44:35-42. DOI PubMed
18. Pan Z, Yilmaz Y, Al-Busafi SA, Eslam M. The MAFLD definition identifies three homogenous groups of patients. Liver Int
2024;Online ahead of print. DOI PubMed
19. Pan Z, Al-Busafi SA, Abdulla M, Fouad Y, Sebastiani G, Eslam M. MAFLD identifies patients with significant hepatic fibrosis better
than MASLD. Hepatol Int 2024;18:964-72. DOI PubMed
20. Pan Z, Derbala M, AlNaamani K, Ghazinian H, Fan JG, Eslam M. MAFLD criteria are better than MASLD criteria at predicting the